Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study

Rodrigo Bremer Nones; Eron Fabio Miranda; Gustavo de Nardi Marçal; Fernanda da Silva Barbosa Baraúna; Marcela Rocha Loures; Paula Cenira Senger; Daniela Oliveira Magro; Paulo Gustavo Kotze

doi:10.1016/j.gastrohep.2023.12.011

Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study

Gastroenterol Hepatol. 2023 Dec 29:S0210-5705(23)00505-8. doi: 10.1016/j.gastrohep.2023.12.011. Online ahead of print.

[Article in English, Spanish]

Authors

Rodrigo Bremer Nones¹, Eron Fabio Miranda², Gustavo de Nardi Marçal², Fernanda da Silva Barbosa Baraúna², Marcela Rocha Loures³, Paula Cenira Senger³, Daniela Oliveira Magro⁴, Paulo Gustavo Kotze²

Affiliations

¹ IBD Unit, Hospital Nossa Senhora das Graças, Curitiba, Brazil. Electronic address: robremernones@gmail.com.
² Colorectal Surgery Unit, Pontifícia Universidade Católica do Paraná, PUCPR, Curitiba, Brazil.
³ IBD Unit, Hospital Nossa Senhora das Graças, Curitiba, Brazil.
⁴ Colorectal Surgery Unit, Universidade Estadual de Campinas, UNICAMP, Campinas, Brazil.

PMID: 38160706
DOI: 10.1016/j.gastrohep.2023.12.011

Abstract

Objectives: In Latin America, experience with monitoring serum Infliximab (IFX) concentrations is scarce. Our study aimed to compare IFX serum concentrations between patients with active disease or in remission.

Patients and methods: A cross-sectional study was performed in patients with luminal Crohn's disease (CD) during maintenance treatment with IFX. Patients were classified as in remission or disease activity according to clinical scores and endoscopic, radiological, and laboratory markers. A comparison of IFX trough levels between the two groups was performed.

Results: 80 CD patients were included [41 (51%) in remission and 39 (49%) with active disease]. In the analysis of general disease activity, the median serum levels of IFX in patients with remission and with active CD were 5.63 [0.03-14.40] vs. 3.84 [0.03-14.40] (p=0.287). Furthermore, there was no difference in serum IFX concentrations in endoscopic, radiological, and laboratory activities. Only in the clinical evaluation there was a significant difference in the median serum IFX levels between patients in remission and disease activity, 5.63 [0.03-14.40] vs. 2.14 [0.32-10.54] (p=0.042).

Conclusions: IFX serum concentrations during maintenance treatment were similar in patients with luminal CD in remission and general, endoscopic, radiological, and laboratory disease activity. Patients with clinically active disease had lower IFX concentrations than patients in remission.

Keywords: Crohn's disease; Dosage; Dosis; Enfermedad de Crohn; Enfermedad inflamatoria intestinal; Inflammatory bowel disease; Infliximab; Monitoreo terapéutico de medicamentos; Nivel mínimo; Therapeutic drug monitoring; Trough level.